JP2019500026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500026A5 JP2019500026A5 JP2018526167A JP2018526167A JP2019500026A5 JP 2019500026 A5 JP2019500026 A5 JP 2019500026A5 JP 2018526167 A JP2018526167 A JP 2018526167A JP 2018526167 A JP2018526167 A JP 2018526167A JP 2019500026 A5 JP2019500026 A5 JP 2019500026A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- attenuated gram
- recombinant attenuated
- negative
- negative strains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims 23
- 239000000589 Siderophore Substances 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 239000012636 effector Substances 0.000 claims 5
- 241000607447 Yersinia enterocolitica Species 0.000 claims 4
- 239000012639 bacterial effector Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 108010077805 Bacterial Proteins Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 claims 1
- 108091006109 GTPases Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000025915 regulation of apoptotic process Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 102000034285 signal transducing proteins Human genes 0.000 claims 1
- 108091006024 signal transducing proteins Proteins 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15195490.6 | 2015-11-19 | ||
| EP15195490 | 2015-11-19 | ||
| PCT/EP2016/078084 WO2017085233A1 (en) | 2015-11-19 | 2016-11-17 | Virulence attenuated bacteria for treatment of malignant solid tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500026A JP2019500026A (ja) | 2019-01-10 |
| JP2019500026A5 true JP2019500026A5 (enExample) | 2021-12-16 |
| JP7060503B2 JP7060503B2 (ja) | 2022-04-26 |
Family
ID=54697464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526167A Active JP7060503B2 (ja) | 2015-11-19 | 2016-11-17 | 悪性固形腫瘍の治療のための弱毒化細菌 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11166987B2 (enExample) |
| EP (2) | EP3903813A1 (enExample) |
| JP (1) | JP7060503B2 (enExample) |
| KR (1) | KR102736981B1 (enExample) |
| CN (1) | CN108472348B (enExample) |
| AU (1) | AU2016358257B2 (enExample) |
| BR (2) | BR122023024697A2 (enExample) |
| CA (1) | CA3003563A1 (enExample) |
| CY (1) | CY1124564T1 (enExample) |
| DK (1) | DK3377094T3 (enExample) |
| EA (1) | EA201890868A1 (enExample) |
| ES (1) | ES2880431T3 (enExample) |
| HR (1) | HRP20211191T1 (enExample) |
| HU (1) | HUE055132T2 (enExample) |
| IL (1) | IL259052B2 (enExample) |
| LT (1) | LT3377094T (enExample) |
| PL (1) | PL3377094T3 (enExample) |
| PT (1) | PT3377094T (enExample) |
| RS (1) | RS62152B1 (enExample) |
| SG (1) | SG11201803643TA (enExample) |
| SI (1) | SI3377094T1 (enExample) |
| SM (1) | SMT202100423T1 (enExample) |
| WO (1) | WO2017085233A1 (enExample) |
| ZA (1) | ZA201803902B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6797025B2 (ja) | 2014-05-21 | 2020-12-09 | ウニヴェルズィテート バーゼル | 細菌に基づくタンパク質送達 |
| KR102689434B1 (ko) | 2015-11-19 | 2024-07-29 | 우니페르시테트 바젤 | 박테리아-기반의 단백질 전달 |
| JP6976351B2 (ja) | 2016-12-20 | 2021-12-08 | ウニヴェルズィテート・バーゼルUniversitat Basel | 弱毒化細菌に基づくタンパク質送達 |
| KR102110993B1 (ko) * | 2018-12-20 | 2020-05-14 | 한국생명공학연구원 | 클레브시엘라 아에로제네스(Klebsiella aerogenes) 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물 |
| AU2021370840A1 (en) * | 2020-10-27 | 2023-06-22 | T3 Pharmaceuticals Ag | Bacteria based protein delivery |
| CN114712496B (zh) * | 2022-04-29 | 2023-10-13 | 中山大学·深圳 | 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用 |
| CN116064877B (zh) * | 2023-02-09 | 2024-09-20 | 宁夏大学 | 利用lamp技术快速检测阴沟肠杆菌的试剂盒及方法 |
| CN116855496B (zh) * | 2023-07-05 | 2024-08-16 | 郑州大学 | 含有干扰序列siRNA-HIF-1α的表达质粒在制备抗肝细胞癌药物中的应用 |
| WO2025037284A2 (en) * | 2023-08-17 | 2025-02-20 | Baccine Ltd. | Genetically modified bacteria for multi-modal secretion of a neoantigen |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965381A (en) * | 1998-03-06 | 1999-10-12 | Ludwig Institute For Cancer Research | Delivery of proteins into eukaryotic cells with recombinant yersinia |
| AU5209399A (en) | 1998-07-10 | 2000-02-01 | Cornell Research Foundation Inc. | Recombinant constructs and systems for secretion of proteins via type iii secretion systems |
| US20020160502A1 (en) | 2000-09-26 | 2002-10-31 | Roger Williams Hospital | Recombinant BCG vaccines for the prevention and treatment of cancer |
| US20040147719A1 (en) | 2001-03-26 | 2004-07-29 | Guy Cornelis | Type III bacterial strains for use in medicine |
| EP1565185A4 (en) | 2002-11-07 | 2011-01-05 | Technion Res & Dev Foundation | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH |
| FR2862312B1 (fr) | 2003-11-13 | 2006-02-17 | Univ Grenoble 1 | Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas |
| WO2007044406A2 (en) | 2005-10-04 | 2007-04-19 | Ludwig Institute For Cancer Research | Methods for stimulating an immune response using bacterial antigen delivery system |
| WO2008019183A2 (en) | 2006-05-18 | 2008-02-14 | The Regents Of The University Of California | Biopolymer and protein production using type iii secretion systems of gram negative bacteria |
| TW200819540A (en) * | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| AU2009226972B2 (en) | 2008-03-17 | 2014-05-29 | Gerhard Heusipp | YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions |
| DK2717886T3 (da) | 2011-06-08 | 2021-12-06 | Chelation Partners Incorporated | Metalchelateringssammensætninger og fremgangsmåder til styring af en levende celles eller organismes vækst eller aktiviteter |
| US9127284B2 (en) * | 2012-05-04 | 2015-09-08 | The University Of Hong Kong | Modified bacteria and their uses thereof for the treatment of cancer or tumor |
| EP3049526B1 (en) | 2013-09-24 | 2021-02-24 | Medicenna Therapeutics, Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| US10143743B2 (en) | 2013-11-18 | 2018-12-04 | Yale University | Non-replicating bacterial nanoparticle delivery system and methods of use |
| JP6797025B2 (ja) | 2014-05-21 | 2020-12-09 | ウニヴェルズィテート バーゼル | 細菌に基づくタンパク質送達 |
| KR102689434B1 (ko) | 2015-11-19 | 2024-07-29 | 우니페르시테트 바젤 | 박테리아-기반의 단백질 전달 |
| JP6976351B2 (ja) | 2016-12-20 | 2021-12-08 | ウニヴェルズィテート・バーゼルUniversitat Basel | 弱毒化細菌に基づくタンパク質送達 |
-
2016
- 2016-11-17 BR BR122023024697-7A patent/BR122023024697A2/pt active Search and Examination
- 2016-11-17 WO PCT/EP2016/078084 patent/WO2017085233A1/en not_active Ceased
- 2016-11-17 RS RS20210926A patent/RS62152B1/sr unknown
- 2016-11-17 EA EA201890868A patent/EA201890868A1/ru unknown
- 2016-11-17 CA CA3003563A patent/CA3003563A1/en active Pending
- 2016-11-17 SM SM20210423T patent/SMT202100423T1/it unknown
- 2016-11-17 PL PL16797930T patent/PL3377094T3/pl unknown
- 2016-11-17 US US15/773,524 patent/US11166987B2/en active Active
- 2016-11-17 DK DK16797930.1T patent/DK3377094T3/da active
- 2016-11-17 CN CN201680079454.XA patent/CN108472348B/zh active Active
- 2016-11-17 HU HUE16797930A patent/HUE055132T2/hu unknown
- 2016-11-17 LT LTEP16797930.1T patent/LT3377094T/lt unknown
- 2016-11-17 PT PT167979301T patent/PT3377094T/pt unknown
- 2016-11-17 HR HRP20211191TT patent/HRP20211191T1/hr unknown
- 2016-11-17 EP EP21170509.0A patent/EP3903813A1/en active Pending
- 2016-11-17 IL IL259052A patent/IL259052B2/en unknown
- 2016-11-17 KR KR1020187016568A patent/KR102736981B1/ko active Active
- 2016-11-17 AU AU2016358257A patent/AU2016358257B2/en active Active
- 2016-11-17 JP JP2018526167A patent/JP7060503B2/ja active Active
- 2016-11-17 BR BR112018009753-5A patent/BR112018009753B1/pt active IP Right Grant
- 2016-11-17 SG SG11201803643TA patent/SG11201803643TA/en unknown
- 2016-11-17 SI SI201631290T patent/SI3377094T1/sl unknown
- 2016-11-17 EP EP16797930.1A patent/EP3377094B1/en active Active
- 2016-11-17 ES ES16797930T patent/ES2880431T3/es active Active
-
2018
- 2018-06-12 ZA ZA2018/03902A patent/ZA201803902B/en unknown
-
2021
- 2021-07-22 CY CY20211100666T patent/CY1124564T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500026A5 (enExample) | ||
| Lin et al. | Biomimetic nanomedicine-triggered in situ vaccination for innate and adaptive immunity activations for bacterial osteomyelitis treatment | |
| Ou et al. | Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application | |
| Yoon et al. | Application of genetically engineered Salmonella typhimurium for interferon-gamma–induced therapy against melanoma | |
| Aganja et al. | Salmonella as a promising curative tool against cancer | |
| EP3957644B1 (en) | Cancer immunotherapy using virus particles | |
| Thangam et al. | Advances in engineered polymer nanoparticle tracking platforms towards cancer immunotherapy—Current status and future perspectives | |
| US11065313B2 (en) | Modified yeast-brachyury immunotherapeutic compositions | |
| Jellbauer et al. | CD8 T-cell induction against vascular endothelial growth factor receptor 2 by Salmonella for vaccination purposes against a murine melanoma | |
| US10220084B2 (en) | Controlled release vaccines and methods of treating Brucella diseases and disorders | |
| WO2015032165A1 (en) | Therapeutic delivery and expression system, methods and uses thereof | |
| Wei et al. | Recent advances in bacteria-based cancer treatment | |
| Sankar | New therapeutic strategies to control and treatment of bovine mastitis | |
| JP2020511139A5 (enExample) | ||
| DK2384190T3 (en) | FORMULATIONS OF LIVELY CELLS FOR ORAL DELIVERY | |
| Bergman | Anticancer vaccines | |
| US10869834B2 (en) | Treatment of inflammatory bowel disease | |
| Bergman | Cancer immunotherapy | |
| Lu et al. | Bacteria-based nanoprobes for cancer therapy | |
| US20240158798A1 (en) | Non-viral gene/carrier complex for prevention or treatment of acute inflammatory disease | |
| Bergman | Cancer immunotherapy | |
| JP2020507332A5 (enExample) | ||
| Wei et al. | In Situ Synthesis of an Immune-Checkpoint Blocker from Engineered Bacteria Elicits a Potent Antitumor Response | |
| JP2013046596A (ja) | 新規な複合体、それを含有する医薬及び癌の治療方法 | |
| Akinsola et al. | Application of Invasive Bacteria for the Delivery of Anti-cancer Therapeutics |